Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

18.55 -0.65 (-3.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,807,140
Open 19.01
Bid (Size) 18.59 (2)
Ask (Size) 18.75 (2)
Prev. Close 19.20
Today's Range 18.53 - 19.11
52wk Range 18.96 - 34.87
Shares Outstanding 88,140,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
The Ark Invest portfolio is known for taking aggressive bets. 
Via The Motley Fool
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Via Benzinga

Performance

YTD
-39.81%
-39.81%
1 Month
-14.20%
-14.20%
3 Month
-16.25%
-16.25%
6 Month
-26.10%
-26.10%
1 Year
-36.93%
-36.93%

More News

Read More
Expert Ratings For Intellia Therapeutics
Via Benzinga
3 Gene Editing Stocks with Potential to Transform Medicine
Via InvestorPlace
NTLA Stock Earnings: Intellia Therapeutics Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Unveiling 6 Analyst Insights On Intellia Therapeutics
Via Benzinga
7 Biotech Stocks to Keep on Your Clinical Radar
Via InvestorPlace
3 Gene Editing Stocks That Could Grow Your Wealth
Via InvestorPlace
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Via InvestorPlace
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
Via Benzinga
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Via InvestorPlace
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Via The Motley Fool
The 3 Best Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Via InvestorPlace
The 3 Best Biotech Stocks to Buy in July 2024
Via InvestorPlace
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
Via Benzinga
Cathie Wood's Ark Invest Sells Tesla Shares Worth $14.5M Amid Rally Driven By Q2 Delivery Numbers, Picks Up Palantir Shares Again Today
Via Benzinga
3 Stocks Cathie Wood Just Bought to Get Back on Track in the Second Half of 2024
Via The Motley Fool
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet
Via InvestorPlace
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
Via InvestorPlace
Cathie Wood's Ark Invest Acquires $7.3M Worth Of Shares In This Promising Netflix Competitor, Sells Off Coinbase Stock Amid Bitcoin Slump
Via Benzinga
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.